PARP1 and cancer: Here we showed that PARP-trapping caused by the PARPi olaparib markedly synergized with non-toxic doses of ATL to result in cancer-specific lethality and co-administration of sublethal doses of olaparib and ATL effectively induced regression of tumor xenografts in vivo.